DialogClassic Web (tm) - Copy/Paste WindowDIALOG(R)File 351:Derwent WPI

013806195 **Image available**
WPI Acc No: 2001-290407/200130
Related WPI Acc No: 2003-401332
XRAM Acc No: C01-088908
Use of a combination of nateglinide with another antidiabetic compound for treating a metabolic disorder, e.g. diabetes and associated conditions, or for effecting weight loss
Patent Assignee: NOVARTIS AG (NOVS); NOVARTIS-ERFINDUNGEN VERW GES MBH (NOVS); ALLISON M (ALLI-I); BALL M A (BALL-I); GATLIN M R (GATL-I); GUITARD C (GUIT-I); KARNACHI A A (KARN-I); MANNION R O (MANN-I)
Inventor: ALLISON M; GATLIN M R; GUITARD C; KARNACHI A A; MANNION R O; PONGOWSKI M; BALL M; KAMACHI A A; BALL M A
Number of Countries: 095 Number of Patents: 014
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200121159	A2	20010329	WO 2000EP9074	A	20000915	200130 B
FR 2798592	A1	20010323	FR 200011782	A	20000915	200130
FI 200100683	A	20010515	WO 2000EP9074	A	20000915	200140
			FI 2001683	A	20010402	
AU 200079044	A	20010424	AU 200079044	A	20000915	200141
CZ 200101723	A3	20010815	WO 2000EP9074	A	20000915	200157
			CZ 20011723	A	20000915	
MX 2001004255	A1	20010801	MX 20014255	A	20010427	200238
EP 1212077	A2	20020612	EP 2000969260	A	20000915	200239
			WO 2000EP9074	A	20000915	
NO 200201197	A	20020516	WO 2000EP9074	A	20000915	200240
			NO 20021197	A	20020311	
BR 200014525	A	20020611	BR 200014525	A	20000915	200248
			WO 2000EP9074	A	20000915	
SK 200200360	A3	20020702	WO 2000EP9074	A	20000915	200253
			SK 2002360	A	20000915	
BE 1013726	A5	20020702	BE 2000585	A	20000915	200257
KR 2002038758	A	20020523	KR 2002703551	A	20020316	200274
JP 2003509457	W	20030311	WO 2000EP9074	A	20000915	200319
			JP 2001524585	A	20000915	
US 20030162816	A1	20030828	US 99240911	P	19990917	200357
			US 2000240918	P	20000309	
			US 2000304196	P	20000407	
			US 2000663264	A	20000915	
			US 2003345908	A	20030116	

Priority Applications (No Type Date): GB 200021055 A 20000826; US 99398364 A 19990917; US 2000545480 A 20000407
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 200121159	A2	E	60	A61K-031/00	

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW

FR 2798592	A1			A61K-031/16	

FI 200100683 A A61K-000/00
AU 200079044 A A61K-031/00 Based on patent WO 200121159
CZ 200101723 A3 A61K-031/198 Based on patent WO 200121159
MX 2001004255 A1 A61K-031/00
EP 1212077 A2 E A61K-038/13 Based on patent WO 200121159
Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
NO 200201197 A A61K-000/00
BR 200014525 A A61K-031/00 Based on patent WO 200121159
SK 200200360 A3 A61K-031/00 Based on patent WO 200121159
BE 1013726 A5 A61K-000/00
KR 2002038758 A A61K-031/64
JP 2003509457 W 83 A61K-031/198 Based on patent WO 200121159
US 20030162816 A1 A61K-031/4439 Provisional application US 99240911

Provisional application US 2000240918
Provisional application US 2000304196
Cont of application US 2000663264

Abstract (Basic): WO 200121159 A2

NOVELTY - Nateglinide (I), optionally in combination with another antidiabetic compound, can be used in the treatment of diabetes and associated conditions. The combination can also be used for effecting weight loss.

DETAILED DESCRIPTION - Use of a combination of nateglinide (I) and at least 1 other antidiabetic compound, selected from thiazolidine derivatives (glitazones), sulfonyl urea derivatives and metformin, present in the free form or as salts, for prevention, delay of progression or treatment of metabolic disorders, or for cosmetic treatment to effect a loss of body weight, is new.

INDEPENDENT CLAIMS are included for the following:

(a) a combination of (I) with an antidiabetic compound (as described above) for simultaneous, sequential or separate use;

(b) compositions comprising (I) with the antidiabetic compound; and

(c) a composition capable of being granulated in the presence of water without the need for a subsequent pulverization step prior to tabletting, comprising (I) and a carrier; and its use for treating a metabolic disorder.

ACTIVITY - Antidiabetic; anorectic; antilipemic; opthalmological; vasotropic; antiulcer; antiinflammatory; cardiant; hypotensive; antianginal; dermatological; antiarthritic; osteopathic; gastrointestinal.

MECHANISM OF ACTION - None given.

USE - For treating a metabolic disorder, e.g. diabetes (particularly type II diabetes mellitus) and associated conditions, also for effecting weight loss. The compositions can be used to treat e.g. hyperglycemia, hyperinsulinemia, hyperlipidemia, insulin resistance, impaired glucose metabolism, obesity, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, glomerulonephritis, diabetic neuropathy, erectile dysfunction, premenstrual syndrome, vascular restenosis, ulcerative colitis, coronary heart disease, hypertension, angina pectoris, myocardial infarction, stroke, skin and connective tissue disorders, foot ulcerations, metabolic acidosis, arthritis, osteoporosis, and conditions of impaired glucose tolerance.

pp; 60 DwgNo 0/0

Technology Focus:

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Compounds: (I) is present in the B-type or H-type crystal modification. The antidiabetic compound is preferably a glitazone, e.g. rosiglitazone, troglitazone or pioglitazone, or metformin or its hydrochloride. Preferred Combination: The combination may further comprise insulin, or comprises at least 2 antidiabetic compounds.

Preferred Composition: A composition comprising (I) and a carrier releases 60-95 wt.% (I) within 30 minutes in water. The composition may further comprise colloidal silicon dioxide, and a disintegrant, preferably having molecular weight greater than 1000000, and particle size distribution of less than 400 microm or less than 74 microm. The composition may be in the form of a tablet, a granular composition, or contained in a capsule.

Title Terms: COMBINATION; ANTIDIABETIC; COMPOUND; TREAT; METABOLISM; DISORDER; DIABETES; ASSOCIATE; CONDITION; EFFECT; WEIGHT; LOSS

Derwent Class: A96; B05

International Patent Class (Main): A61K-000/00; A61K-031/00; A61K-031/16; A61K-031/198; A61K-031/4439; A61K-031/64; A61K-038/13

International Patent Class (Additional): A61K-009/16; A61K-009/20; A61K-009/48; A61K-031/155; A61K-031/175; A61K-031/195; A61K-031/425; A61K-031/426; A61K-031/44; A61K-031/4433; A61K-031/63; A61K-038/28; A61K-047/04; A61K-047/12; A61K-047/26; A61K-047/32; A61K-047/38; A61P-001/00; A61P-001/04; A61P-003/00; A61P-003/04; A61P-003/10; A61P-009/00; A61P-009/10; A61P-009/12; A61P-013/12; A61P-015/00; A61P-015/10; A61P-017/00; A61P-019/02; A61P-019/10; A61P-027/06; A61P-027/12; A61K-031/198; A61K-031-155; A61K-031-425; A61K-031-64; A61K-031/16; A61K-031-427

File Segment: CPI

Manual Codes (CPI/A-N): A12-V01; B04-C02A1; B04-C02A2; B04-C03A; B05-B02C; B06-A01; B07-A02B; B07-D04C; B07-F01; B10-A17; B10-C04A; B10-C04E; B12-M11B; B14-E12; B14-R01; B14-S04

Chemical Fragment Codes (M1):

07 M423 M431 M782 M904 M905 M910 Q120 Q254 R038 R01852-K R01852-M

08 F011 F012 F423 H2 H211 H7 H713 H721 J5 J521 L9 L941 M210 M212 M273 M281 M320 M423 M431 M510 M521 M530 M540 M782 M904 M905 Q120 Q254 R038 RA04WZ-K RA04WZ-M

09 A111 A960 C710 M423 M431 M630 M782 M904 M905 Q120 Q254 R038 RA002Y-K RA002Y-M

Chemical Fragment Codes (M2):

01 G010 G035 G111 G563 J0 J012 J1 J171 J3 J351 M210 M213 M232 M240 M281 M312 M321 M332 M343 M349 M371 M391 M414 M431 M510 M520 M531 M541 M781 M782 M904 M905 P731 P816 Q120 Q254 R031 R032 R038 RA27XA-K RA27XA-T RA27XA-M RA27XA-U

02 K0 L2 L240 M210 M211 M273 M282 M320 M416 M431 M620 M782 M904 M905 P731 P816 Q120 Q254 R031 R032 R038 R14399-K R14399-T R14399-M

03 C017 C100 C800 C801 C803 C804 C805 C806 C807 K0 L2 L240 M210 M211 M273 M282 M320 M411 M431 M510 M520 M530 M540 M620 M640 M782 M904 M905 P731 P816 Q120 Q254 R031 R032 R038 RA0MPQ-K RA0MPQ-T RA0MPQ-M

04 F012 F014 F015 F019 F431 F710 G013 G100 H1 H103 H121 H5 H541 H8 J5 J522 L9 L910 M1 M123 M132 M210 M211 M273 M281 M311 M312 M321 M332 M342 M383 M391 M413 M431 M510 M522 M531 M540 M782 M904 M905 P731 P816 Q120 Q254 R031 R032 R038 RA052X-K RA052X-T RA052X-M

05 D012 D016 D025 D120 F012 F014 F015 F710 G013 G100 H4 H401 H441 H5 H541 H8 J5 J522 L9 L910 M1 M123 M132 M210 M211 M240 M283 M311 M322 M342 M373 M391 M412 M431 M511 M521 M531 M540 M782 M904 M905 P731

P816 Q120 Q254 R031 R032 R038 RA052J-K RA052J-T RA052J-M
06 F012 F014 F015 F019 F431 F710 G013 G100 H5 H541 H8 J5 J522 L9 L910
M1 M123 M132 M210 M212 M240 M281 M311 M312 M321 M332 M342 M373 M391
M413 M431 M510 M522 M531 M540 M782 M904 M905 P731 P816 Q120 Q254
R031 R032 R038 R23694-K R23694-T R23694-M
Polymer Indexing (PS):
<01>
001 018; G0635 G0022 D01 D12 D10 D23 D22 D31 D41 D51 D53 D58 D75 D86
F71; H0000; M9999 M2073
002 018; ND01; Q9999 Q8037 Q7987; Q9999 Q7250
003 018; B9999 B5094 B4977 B4740; B9999 B5209 B5185 B4740
<02>
001 018; R24033 G3714 P0599 D01 F70; S9999 S1423 S1401
002 018; ND01; Q9999 Q8037 Q7987; Q9999 Q7250
<03>
001 018; R01852-R G3634 D01 D03 D11 D10 D23 D22 D31 D42 D50 D76 D86 F24
F29 F26 F34 H0293 P0599 G3623
002 018; ND01; Q9999 Q8037 Q7987; Q9999 Q7250
003 018; Q9999 Q9347; B9999 B4795 B4773 B4740
Derwent Registry Numbers: 1694-U; 1852-U
Specific Compound Numbers: RA27XA-K; RA27XA-T; RA27XA-M; RA27XA-U; R14399-K
; R14399-T; R14399-M; RA0MPQ-K; RA0MPQ-T; RA0MPQ-M; RA052X-K; RA052X-T;
RA052X-M; RA052J-K; RA052J-T; RA052J-M; R23694-K; R23694-T; R23694-M;
R01852-K; R01852-M; RA04WZ-K; RA04WZ-M; RA002Y-K; RA002Y-M; RA1Z26-K;
RA1Z26-M; R01694-K; R01694-M; R01376-K; R01376-M
Key Word Indexing Terms:
01 123381-1-0-0-CL, USE 26073-0-0-0-CL 26073-0-1-0-CL, ST
111925-0-0-0-CL 109523-0-0-0-CL 111061-0-0-0-CL 90356-0-0-0-CL
104488-0-0-0-CL 91820-0-0-0-CL 295347-1-0-0-CL 107016-0-0-0-CL
2021-0-1-0-CL, ST
?